Brief: Aeterna Zentaris Expands Orphan Drug Development Pipeline With Targeted Immunosuppressive Therapeutics

COSCIENS Biopharma

28/01/2021 17:25

Jan 28 (Reuters) - Aeterna Zentaris Inc  AEZS.TO :
    * AETERNA ZENTARIS EXPANDS ORPHAN DRUG DEVELOPMENT PIPELINE
WITH
TARGETED IMMUNOSUPPRESSIVE THERAPEUTICS
    * AETERNA ZENTARIS INC - TO DEVELOP POTENTIAL THERAPEUTIC
TREATMENT OPTION FOR NEUROMYELITIS OPTICA SPECTRUM DISORDER
    * AETERNA ZENTARIS - GOT WORLDWIDE RIGHTS TO MAKE,
COMMERCIALIZE
PRODUCTS FOR NMOSD TREATMENT FOR UP-FRONT CASH PAY OF EUR
100,000, MILESTONE PAYMENTS
    * AETERNA ZENTARIS-LICENSED WORLDWIDE RIGHTS OF TARGETED,
HIGHLY
SPECIFIC, AUTOIMMUNITY MODIFYING PROTEINS FROM
JULIUS-MAXIMILIANS-UNIVERSITY WUERZBURG

Source text for Eikon:  ID:nGNX41v65Q 
Further company coverage:  AEZS.TO 

 ((Reuters.Briefs@thomsonreuters.com;))